Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: Biological and clinical implications

British Journal of Haematology

Volumn 152, Issue 4, 2011, Pages 420-432

  McMillin, Douglas W ^a,b   Delmore, Jake ^a,b   Negri, Joseph ^a,b   Buon, Leutz ^a,b   Jacobs, Hannah M ^a,b   Laubach, Jacob ^a,b   Jakubikova, Jana ^a,b   Ooi, Melissa ^a,b   Hayden, Patrick ^a,b   Schlossman, Robert ^a   Munshi, Nikhil C ^a,d   Lengauer, Christoph ^c   Richardson, Paul G ^a,b   Anderson, Kenneth C ^a,b   Mitsiades, Constantine S ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^d VA BOSTON HEALTHCARE SYSTEM   (United States)

Author keywords

Cancer; Cyclin dependent kinases; Kinase inhibitor; Microenvironment; Myeloma

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 3; CYCLIN DEPENDENT KINASE 5; CYCLIN DEPENDENT KINASE 9; CYCLIN DEPENDENT KINASE INHIBITOR; CYTOKINE; DEXAMETHASONE; DOXORUBICIN; FLAVOPIRIDOL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERFERON REGULATORY FACTOR 4; LCQ 195; MYC PROTEIN; PACLITAXEL; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER RESISTANCE; CANCER SURVIVAL; CELL CYCLE ARREST; CELL RENEWAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; STEM CELL; TRANSCRIPTION INITIATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CELL CYCLE; CELL SURVIVAL; COCULTURE TECHNIQUES; CYCLIN-DEPENDENT KINASES; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG COMBINATIONS; DRUG INTERACTIONS; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MULTIPLE MYELOMA; PYRAZINES; SIGNAL TRANSDUCTION; STROMAL CELLS; SURVIVAL ANALYSIS; TRANSCRIPTION, GENETIC; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 78851470347     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08427.x     Document Type: Article

References (45)

1. Attal, M., Harousseau, J.L., Leyvraz, S., Doyen, C., Hulin, C., Benboubker, L., Yakoub Agha, I., Bourhis, J.H., Garderet, L., Pegourie, B., Dumontet, C., Renaud, M., Voillat, L., Berthou, C., Marit, G., Monconduit, M., Caillot, D., Grobois, B., Avet-Loiseau, H., Moreau, P. & Facon, T. (2006) Maintenance therapy with thalidomide improves survival in multiple myeloma patients. Blood, 108, 3289-3294.
2. Barlogie, B., Desikan, R., Eddlemon, P., Spencer, T., Zeldis, J., Munshi, N., Badros, A., Zangari, M., Anaissie, E., Epstein, J., Shaughnessy, J., Ayers, D., Spoon, D. & Tricot, G. (2001) Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood, 98, 492-494.
3. Bergsagel, P.L. & Kuehl, W.M. (2005) Molecular pathogenesis and a consequent classification of multiple myeloma. Journal of Clinical Oncology, 23, 6333-6338.
4. Bergsagel, P.L., Kuehl, W.M., Zhan, F., Sawyer, J., Barlogie, B. & Shaughnessy, Jr, J. (2005) Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood, 106, 296-303.
5. Carrasco, R.D., Sukhdeo, K., Protopopova, M., German, M., Henderson, J., Anderson, K.C. & DePinho, R.A. (2005) Targeted overexpression of the transcription factor XBP-1 in B cells promotes plasma cell and lymphoplasmacytic neoplasms in transgenic mice. Blood, 106, 109A.
6. Conroy, A., Stockett, D.E., Walker, D., Arkin, M.R., Hoch, U., Fox, J.A. & Hawtin, R.E. (2009) SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples. Cancer Chemotherapy and Pharmacology, 64, 723-732.
7. Dai, Y., Hamm, T.E., Dent, P. & Grant, S. (2006) Cyclin D1 overexpression increases the susceptibility of human U266 myeloma cells to CDK inhibitors through a process involving p130-, p107- and E2F-dependent S phase entry. Cell Cycle, 5, 437-446.
8. Dimopoulos, M, Spencer, A, Attal, M, Prince, HM., Harousseau, JL, Dmoszynska, A, San Miguel, J, Hellmann, A, Facon, T, Foá, R, Corso, A, Masliak, Z, Olesnyckyj, M, Yu, Z, Patin, J, Zeldis, JB, Knight, RD; Multiple Myeloma (010) Study Investigators. (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 357, 2123-2132.
9. Duffin, R., Leitch, A.E., Sheldrake, T.A., Hallett, J.M., Meyer, C., Fox, S., Alessandri, A.L., Martin, M.C., Brady, H.J., Teixeira, M.M., Dransfield, I., Haslett, C. & Rossi, A.G. (2009) The CDK inhibitor, R-roscovitine, promotes eosinophil apoptosis by down-regulation of Mcl-1. FEBS Letters, 583, 2540-2546.
10. Garcia-Sanz, R., Gonzalez-Fraile, M.I., Mateo, G., Hernandez, J.M., Lopez-Berges, M.C., de las Heras, N., Fernandez-Calvo, J., Ortega, F., Portero, J.A., Barez, A., Galende, J., Orfao, A. & San Miguel, J.F. (2004) Proliferative activity of plasma cells is the most relevant prognostic factor in elderly multiple myeloma patients. International Journal of Cancer, 112, 884-889.
11. Gojo, I., Zhang, B. & Fenton, R.G. (2002) The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clinical Cancer Research, 8, 3527-3538.
12. van den Heuvel, S. & Harlow, E. (1993) Distinct roles for cyclin-dependent kinases in cell cycle control. Science, 262, 2050-2054.
13. Hideshima, T., Chauhan, D., Shima, Y., Raje, N., Davies, F.E., Tai, Y.T., Treon, S.P., Lin, B., Schlossman, R.L., Richardson, P., Muller, G., Stirling, D.I. & Anderson, K.C. (2000) Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood, 96, 2943-2950.
14. Hideshima, T., Bergsagel, P.L., Kuehl, W.M. & Anderson, K.C. (2004) Advances in biology of multiple myeloma: clinical applications. Blood, 104, 607-618.
15. Hu, J., Bianchi, F., Ferguson, M., Cesario, A., Margaritora, S., Granone, P., Goldstraw, P., Tetlow, M., Ratcliffe, C., Nicholson, A.G., Harris, A., Gatter, K. & Pezzella, F. (2005) Gene expression signature for angiogenic and nonangiogenic non-small-cell lung cancer. Oncogene, 24, 1212-1219.
16. Lacrima, K., Rinaldi, A., Vignati, S., Martin, V., Tibiletti, M.G., Gaidano, G., Catapano, C.V. & Bertoni, F. (2007) Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas. Leukaemia & Lymphoma, 48, 158-167.
17. Lee, A.H., Iwakoshi, N.N. & Glimcher, L.H. (2003) XBP-1 regulates a subset of endoplasmic reticulum resident chaperone genes in the unfolded protein response. Molecular and Cellular Biology, 23, 7448-7459.
18. Leonard, M.O., Cottell, D.C., Godson, C., Brady, H.R. & Taylor, C.T. (2003) The role of HIF-1 alpha in transcriptional regulation of the proximal tubular epithelial cell response to hypoxia. Journal of Biological Chemistry, 278, 40296-40304.
19. MacCallum, D.E., Melville, J., Frame, S., Watt, K., Anderson, S., Gianella-Borradori, A., Lane, D.P. & Green, S.R. (2005) Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Research, 65, 5399-5407.
20. Manalo, D.J., Rowan, A., Lavoie, T., Natarajan, L., Kelly, B.D., Ye, S.Q., Garcia, J.G. & Semenza, G.L. (2005) Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood, 105, 659-669.
21. McMillin, D.W., Delmore, J., Weisberg, E., Negri, J.M., Geer, D.C., Klippel, S., Mitsiades, N., Schlossman, R.L., Munshi, N.C., Kung, A.L., Griffin, J.D., Richardson, P.G., Anderson, K.C. & Mitsiades, C.S. (2010) Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nature Medicine, 16, 483-489.
22. Mense, S.M., Sengupta, A., Zhou, M., Lan, C., Bentsman, G., Volsky, D.J. & Zhang, L. (2006) Gene expression profiling reveals the profound upregulation of hypoxia-responsive genes in primary human astrocytes. Physiological Genomics, 25, 435-449.
23. Menu, E., Garcia, J., Huang, X., Di Liberto, M., Toogood, P.L., Chen, I., Vanderkerken, K. & Chen-Kiang, S. (2008) A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model. Cancer Research, 68, 5519-5523.
24. Mitsiades, C.S., Treon, S.P., Mitsiades, N., Shima, Y., Richardson, P., Schlossman, R., Hideshima, T. & Anderson, K.C. (2001) TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood, 98, 795-804.
25. Mitsiades, N., Mitsiades, C.S., Poulaki, V., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M., Libermann, T.A., Treon, S.P., Munshi, N.C., Richardson, P.G., Hideshima, T. & Anderson, K.C. (2002) Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proceedings of the National Academy of Sciences of the United States of America, 99, 14374-14379.
26. Mitsiades, C.S., Mitsiades, N.S., McMullan, C.J., Poulaki, V., Shringarpure, R., Akiyama, M., Hideshima, T., Chauhan, D., Joseph, M., Libermann, T.A., Garcia-Echeverria, C., Pearson, M.A., Hofmann, F., Anderson, K.C. & Kung, A.L. (2004a) Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell, 5, 221-230.
27. Mitsiades, C.S., Mitsiades, N.S., McMullan, C.J., Poulaki, V., Shringarpure, R., Hideshima, T., Akiyama, M., Chauhan, D., Munshi, N., Gu, X., Bailey, C., Joseph, M., Libermann, T.A., Richon, V.M., Marks, P.A. & Anderson, K.C. (2004b) Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proceedings of the National Academy of Sciences of the United States of America, 101, 540-545.
28. Raje, N., Kumar, S., Hideshima, T., Roccaro, A., Ishitsuka, K., Yasui, H., Shiraishi, N., Chauhan, D., Munshi, N.C., Green, S.R. & Anderson, K.C. (2005) Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood, 106, 1042-1047.
29. Rajkumar, S.V., Fonseca, R., Dispenzieri, A., Lacy, M.Q., Witzig, T.E., Lust, J.A., Larson, D., Therneau, T.M., Kyle, R.A., Litzow, M.R., Greipp, P.R. & Gertz, M.A. (2000) Effect of complete response on outcome following autologous stem cell transplantation for myeloma. Bone Marrow Transplantation, 26, 979-983.
30. Rajkumar, S.V., Fonseca, R., Dispenzieri, A., Lacy, M.Q., Lust, J.A., Witzig, T.E., Therneau, T.M., Kyle, R.A., Greipp, P.R. & Gertz, M.A. (2001) Methods for estimation of bone marrow plasma cell involvement in myeloma: predictive value for response and survival in patients undergoing autologous stem cell transplantation. American Journal of Hematology, 68, 269-275.
31. Richardson, P.G., Schlossman, R.L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L.P., Doss, D., Kelly, K., McKenney, M., Mechlowicz, J., Freeman, A., Deocampo, R., Rich, R., Ryoo, J.J., Chauhan, D., Balinski, K., Zeldis, J. & Anderson, K.C. (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood, 100, 3063-3067.
32. Richardson, P.G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S.V., Srkalovic, G., Alsina, M., Alexanian, R., Siegel, D., Orlowski, R.Z., Kuter, D., Limentani, S.A., Lee, S., Hideshima, T., Esseltine, D.L., Kauffman, M., Adams, J., Schenkein, D.P. & Anderson, K.C. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. New England Journal of Medicine, 348, 2609-2617.
33. Richardson, P.G., Sonneveld, P., Schuster, M.W., Irwin, D., Stadtmauer, E.A., Facon, T., Harousseau, J.L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., San-Miguel, J.F., Blade, J., Boccadoro, M., Cavenagh, J., Dalton, W.S., Boral, A.L., Esseltine, D.L., Porter, J.B., Schenkein, D. & Anderson, K.C. (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. New England Journal of Medicine, 352, 2487-2498.
34. Richardson, P.G., Blood, E., Mitsiades, C.S., Jagannath, S., Zeldenrust, S.R., Alsina, M., Schlossman, R.L., Rajkumar, S.V., Desikan, K.R., Hideshima, T., Munshi, N.C., Kelly-Colson, K., Doss, D., McKenney, M.L., Gorelik, S., Warren, D., Freeman, A., Rich, R., Wu, A., Olesnyckyj, M., Wride, K., Dalton, W.S., Zeldis, J., Knight, R., Weller, E. & Anderson, K.C. (2006) A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 108, 3458-3464.
35. Semenov, I., Akyuz, C., Roginskaya, V., Chauhan, D. & Corey, S.J. (2002) Growth inhibition and apoptosis of myeloma cells by the CDK inhibitor flavopiridol. Leukemia Research, 26, 271-280.
36. Semenza, G.L. (2001) Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. Trends in Molecular Medicine, 7, 345-350.
37. Shaffer, A.L., Emre, N.C., Lamy, L., Ngo, V.N., Wright, G., Xiao, W., Powell, J., Dave, S., Yu, X., Zhao, H., Zeng, Y., Chen, B., Epstein, J. & Staudt, L.M. (2008) IRF4 addiction in multiple myeloma. Nature, 454, 226-231.
38. Shapiro, G.I. (2006) Cyclin-dependent kinase pathways as targets for cancer treatment. Journal of Clinical Oncology, 24, 1770-1783.
39. Shaughnessy, Jr, J.D., Zhan, F., Burington, B.E., Huang, Y., Colla, S., Hanamura, I., Stewart, J.P., Kordsmeier, B., Randolph, C., Williams, D.R., Xiao, Y., Xu, H., Epstein, J., Anaissie, E., Krishna, S.G., Cottler-Fox, M., Hollmig, K., Mohiuddin, A., Pineda-Roman, M., Tricot, G., van Rhee, F., Sawyer, J., Alsayed, Y., Walker, R., Zangari, M., Crowley, J. & Barlogie, B. (2007) A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood, 109, 2276-2284.
40. Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., Zeddis, J. & Barlogie, B. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. New England Journal of Medicine, 341, 1565-1571.
41. Stromberg, T., Ekman, S., Girnita, L., Dimberg, L.Y., Larsson, O., Axelson, M., Lennartsson, J., Hellman, U., Carlson, K., Osterborg, A., Vanderkerken, K., Nilsson, K. & Jernberg-Wiklund, H. (2006) IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells. Blood, 107, 669-678.
42. Weber, DM, Chen, C, Niesvizky, R, Wang, M, Belch, A, Stadtmauer, EA, Siegel, D, Borrello, I, Rajkumar, SV, Chanan-Khan, AA, Lonial, S, Yu, Z, Patin, J, Olesnyckyj, M, Zeldis, JB, Knight, RD, Multiple Myeloma (009) Study Investigators. (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 357, 2133-2142.
43. Wyatt, P.G., Woodhead, A.J., Berdini, V., Boulstridge, J.A., Carr, M.G., Cross, D.M., Davis, D.J., Devine, L.A., Early, T.R., Feltell, R.E., Lewis, E.J., McMenamin, R.L., Navarro, E.F., O'Brien, M.A., O'Reilly, M., Reule, M., Saxty, G., Seavers, L.C., Smith, D.M., Squires, M.S., Trewartha, G., Walker, M.T. & Woolford, A.J. (2008) Identification of N-(4-piperidinyl)-4-(2, 6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. Journal of Medicinal Chemistry, 51, 4986-4999.
44. Yu, D., Cozma, D., Park, A. & Thomas-Tikhonenko, A. (2005) Functional validation of genes implicated in lymphomagenesis: an in vivo selection assay using a Myc-induced B-cell tumor. Annals of the New York Academy of Sciences, 1059, 145-159.
45. Zeller, K.I., Jegga, A.G., Aronow, B.J., O'Donnell, K.A. & Dang, C.V. (2003) An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. Genome Biology, 4, R69.